Stocks in the News: The GEO Group Inc (NYSE:GEO), Clean Energy Fuels Corp (NASDAQ:CLNE)

On Tuesday, Shares of The GEO Group Inc (NYSE:GEO), included 1.42% and shut at $32.09 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $31.88 and $32.40. The GEO Group, Inc. provides government-outsourced services specializing in the administration of correctional, detention, and re-entry facilities, and the provision of community based services and youth services in the United States, Australia, South Africa, the United Kingdom, and Canada. It operates through four segments: U.S. Corrections & Detention, GEO Community Services, International Services, and Facility Construction & Design. The company owns, leases, and operates a range of correctional and detention facilities, counting maximum, medium, and minimum security prisons; immigration detention centers; minimum security detention centers; and community based re-entry facilities. It offers correctional and detention administration services that involves the provision of security, administrative, rehabilitation, education, and food services mainly at adult male correctional and detention facilities; engages in the supervision of adult parolees and probationers, in addition to the provision of temporary housing, programming, employment assistance, and other services; and provides residential, detention, shelter care, and community based services with rehabilitative and educational programs.

Shares of Clean Energy Fuels Corp (NASDAQ:CLNE), subtract -1.34% and shut at $3.68 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $3.63 and $3.78. The association’s commercial center capitalization is $514.61 million with the general uncommon loads of 136.84 million. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has partnershipagreements with Celgene Corporation, Editas Medicine, Inc., Fate Therapeutics, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center.

Leave a Reply

Your email address will not be published. Required fields are marked *